Publications by authors named "B Rolland"
Background: Dry January is a one-month alcohol abstinence challenge for the general population running since 2013 in the United Kingdom, and 2020 in France. Dry January has gained increasing popularity among the public, but studies assessing the individual characteristics associated with awareness and participation remain sparse.
Methods: Using quota sampling, a representative sample of 5,000 French adults completed an online cross-sectional survey between 8 and 17th January 2024.
Article Synopsis
- Substance misuse among healthcare residents in a French city is linked to environmental factors, especially working conditions and social support.
- An online survey revealed high rates of substance misuse, with over half showing alcohol misuse and notable differences in misuse based on residency specialty.
- Low social support at work increases the risk of illicit drug use, while working long hours did not have a significant association with substance misuse.
Background: Pregabalin is a drug approved for neuropathic pain, epilepsy and general anxiety disorder. However, pregabalin is also an increasing cause of diversion and misuse, and, for this reason, the French health authorities have decided in 2021 to classify it as a narcotic drug, requiring secured prescription pads. Our study aimed to evaluate the impact of this measure on pregabalin dispensation patterns.
View Article and Find Full Text PDFPurpose: In 2017, the National Cancer Institute (NCI) funded the Cancer Center Cessation Initiative (C3I) to implement and expand tobacco treatment programs in routine oncology care. Many C3I programs developed specialty care programs staffed by tobacco treatment specialists (TTSs) to deliver evidence-based treatment to adult patients who smoke. People involved in specialty tobacco treatment programs can help to identify implementation strategies and adaptations that may enhance tobacco treatment reach and effectiveness in cancer care and help more patients with cancer quit using tobacco.
View Article and Find Full Text PDFAim: The long-acting buprenorphine Buvidal® is a recent type of opioid agonist treatment (OAT) used for opioid use disorder (OUD). It was initially suggested to preferentially use Buvidal® for specific OUD populations, including people in prison, or patients in recovery and on sublingual buprenorphine. We conducted a national study to examine whether the profile of patients treated with Buvidal® in France matched these initial recommendations.
View Article and Find Full Text PDF